+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acute Myeloid Leukemia (AML) Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • PDF Icon

    Report

  • 118 Pages
  • August 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5701942
Description Jump to:

Acute myeloid leukemia (AML) is type of blood and bone marrow cancer characterized by abnormal production of myeloid blasts in the bone marrow and peripheral blood. Rising incidence of AML, higher number of unmet needs, expected launch of ideal molecules and technological advances are prime factors that driving the growth of AML therapeutics market globally.

The report titled Acute Myeloid Leukemia (AML) therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2022-2030; offers strategic insights into the overall AML therapeutics market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on drug type (chemotherapy drugs and pipeline drugs) and different geographical regions.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global AML therapeutics market. Pipeline analysis and global epidemiology data has been included in report. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global AML therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global AML therapeutics market. In-depth competitive environment analysis and historical years (2019) market size data are also provided in the report.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Acute Myeloid Leukemia (AML) Therapeutics market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Acute Myeloid Leukemia (AML) Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drugs

  • Cell Culture Vaccines
  • Cytarabine
  • Anthracyclines
  • Etoposide
  • Others
  • Pipeline Drugs

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Acute Myeloid Leukemia (AML) Therapeutics market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Acute Myeloid Leukemia (AML) Therapeutics market?
  • Which is the largest regional market for Acute Myeloid Leukemia (AML) Therapeutics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Acute Myeloid Leukemia (AML) Therapeutics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Acute Myeloid Leukemia (AML) Therapeutics market worldwide?


This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Acute Myeloid Leukemia (AML) Therapeutics Market
2.2. Global Acute Myeloid Leukemia (AML) Therapeutics Market, By Drugs, 2021 (US$ Million)
2.3. Global Acute Myeloid Leukemia (AML) Therapeutics Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021
3. Acute Myeloid Leukemia (AML) Therapeutics Market: Competitive Analysis
3.1. Market Positioning of Key Acute Myeloid Leukemia (AML) Therapeutics Market Vendors
3.2. Strategies Adopted by Acute Myeloid Leukemia (AML) Therapeutics Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Acute Myeloid Leukemia (AML) Therapeutics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Acute Myeloid Leukemia (AML) Therapeutics Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Cell Culture Vaccines
5.3.1.1. Cytarabine
5.3.1.2. Anthracyclines
5.3.1.3. Etoposide
5.3.1.4. Others
5.3.2. Pipeline Drugs
6. North America Acute Myeloid Leukemia (AML) Therapeutics Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
6.3.Acute Myeloid Leukemia (AML) Therapeutics Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
7. UK and European Union Acute Myeloid Leukemia (AML) Therapeutics Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
7.3.Acute Myeloid Leukemia (AML) Therapeutics Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
8. Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
8.3.Acute Myeloid Leukemia (AML) Therapeutics Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
9. Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
9.3.Acute Myeloid Leukemia (AML) Therapeutics Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
10. Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
10.3.Acute Myeloid Leukemia (AML) Therapeutics Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
11. Company Profile
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Astex Pharmaceuticals (A subsidiary of Otsuka Pharmaceutical)
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Boehringer Ingelheim GmbH
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Bristol Myers Squibb
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Celegene Corporation
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Cephalon Inc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Eisai Co. Ltd.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Eli Lilly and Company
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Genzyme Corporation (A subsidiary of Sanofi S.A.)
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Jazz Pharmaceuticals, Inc.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Novartis AG
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Pfizer Inc.
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
List of Figures
Figure 1 Global Acute Myeloid Leukemia (AML) Therapeutics Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Acute Myeloid Leukemia (AML) Therapeutics Market: Quality Assurance
Figure 5 Global Acute Myeloid Leukemia (AML) Therapeutics Market, By Drugs, 2021
Figure 6 Global Acute Myeloid Leukemia (AML) Therapeutics Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Acute Myeloid Leukemia (AML) Therapeutics Market, 2021
Figure 8 Market Positioning of Key Acute Myeloid Leukemia (AML) Therapeutics Market Players, 2021
Figure 9 Global Acute Myeloid Leukemia (AML) Therapeutics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Acute Myeloid Leukemia (AML) Therapeutics Market, By Drugs, 2021 Vs 2030, %
Figure 11 U.S. Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 12 Canada Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 14 UK Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 15 Germany Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 16 Spain Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 17 Italy Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 18 France Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 20 China Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 21 Japan Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 22 India Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 23 Australia Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 24 South Korea Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 26 Brazil Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 27 Mexico Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 29 GCC Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 30 Africa Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 2 Global Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 3 North America Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 4 North America Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 5 U.S. Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 6 U.S. Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 7 Canada Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 8 Canada Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 9 Rest of North America Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 10 Rest of North America Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 11 UK and European Union Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 12 UK and European Union Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 13 UK Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 14 UK Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 15 Germany Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 16 Germany Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 17 Spain Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 18 Spain Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 19 Italy Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 20 Italy Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 21 France Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 22 France Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 23 Rest of Europe Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 24 Rest of Europe Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 25 Asia Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 26 Asia Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 27 China Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 28 China Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 29 Japan Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 30 Japan Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 31 India Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 32 India Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 33 Australia Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 34 Australia Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 35 South Korea Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 36 South Korea Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 37 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 38 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 39 Brazil Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 40 Brazil Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 41 Mexico Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 42 Mexico Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 43 Rest of Latin America Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 44 Rest of Latin America Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 45 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 46 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 47 GCC Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 48 GCC Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 49 Africa Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 50 Africa Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)
Table 51 Rest of Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs, 2020-2030, USD (Million)
Table 52 Rest of Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market By Cell Culture Vaccines, 2020-2030, USD (Million)

Companies Mentioned

  • Abbott Laboratories
  • Astex Pharmaceuticals (A subsidiary of Otsuka Pharmaceutical)
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb
  • Celegene Corporation
  • Cephalon Inc.
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • Genzyme Corporation (A subsidiary of Sanofi S.A.)
  • Jazz Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc. 

Related Topics

Related Reports

Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report - Product Image

Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report

  • Report
  • 356 Pages
  • Global
From
Acute Myeloid Leukemia Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 - Product Image

Acute Myeloid Leukemia Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • Report
  • 148 Pages
  • Global
From
Global Acute Myeloid Leukemia Therapeutics Market (AML) by Disease Type (Myeloblastic, Myelomonocytic, Promyelocytic), Treatment Type (Chemotherapy, Targeted Therapy), Distribution Channel - Forecast 2024-2030 - Product Image

Global Acute Myeloid Leukemia Therapeutics Market (AML) by Disease Type (Myeloblastic, Myelomonocytic, Promyelocytic), Treatment Type (Chemotherapy, Targeted Therapy), Distribution Channel - Forecast 2024-2030

  • Report
  • 182 Pages
  • Global
From
Global Acute Myeloid Leukemia Therapeutics Market by Disease Type, Treatment Type, Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Forecast 2023-2030 - Product Image

Global Acute Myeloid Leukemia Therapeutics Market by Disease Type, Treatment Type, Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Forecast 2023-2030

  • Report
  • 187 Pages
  • Global
From
Relapsed Acute Myeloid Leukemia Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Relapsed Acute Myeloid Leukemia Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 97 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.